Association between serum indoxyl sulfate levels with carotid-femoral pulse wave velocity in patients with chronic kidney disease

References

• Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–830.
   PubMed Web of Science ®Google Scholar
• Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87(7):E10–E17.
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–1327.
   PubMed Web of Science ®Google Scholar
• Karras A, Haymann JP, Bozec E, et al. Large artery stiffening and remodeling are independently associated with all-cause mortality and cardiovascular events in chronic kidney disease. Hypertension. 2012;60(6):1451–1457.
   PubMed Web of Science ®Google Scholar
• Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J. 2010;31(19):2338–2350.
   PubMed Web of Science ®Google Scholar
• London GM, Safar ME, Pannier B. Aortic aging in ESRD: structural, hemodynamic, and mortality implications. JASN. 2016;27(6):1837–1846.
   Web of Science ®Google Scholar
• Ilyas B, Dhaun N, Markie D, et al. Renal function is associated with arterial stiffness and predicts outcome in patients with coronary artery disease. QJM. 2008;102(3):183–191.
   Web of Science ®Google Scholar
• Ford ML, Tomlinson LA, Chapman TP, et al. Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension. 2010;55(5):1110–1115.
   PubMed Web of Science ®Google Scholar
• Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension. 2009;54(6):1328–1336.
   PubMed Web of Science ®Google Scholar
• Yapei Y, Xiaoyan R, Sha Z, et al. Clinical significance of arterial stiffness and thickness biomarkers in type 2 diabetes mellitus: an Up-To-date meta-analysis. Med Sci Monit. 2015;21:2467–2475.
   PubMed Web of Science ®Google Scholar
• Milanesi S, Garibaldi S, Saio M, et al. Indoxyl sulfate induces renal fibroblast activation through a targetable heat shock protein 90-dependent pathway. Oxid Med Cell Longevity. 2019;2019:1–11.
   Web of Science ®Google Scholar
• Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One. 2012;7(3):e34026.
   PubMed Web of Science ®Google Scholar
• Kim SH, Yu MA, Ryu ES, et al. Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Lab Invest. 2012;92(4):488–498.
   PubMed Web of Science ®Google Scholar
• Vanholder R, Schepers E, Pletinck A, et al. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. JASN. 2014;25(9):1897–1907.
   Web of Science ®Google Scholar
• Wang CH, Lai YH, Kuo CH, et al. Association between serum indoxyl sulfate levels and endothelial function in non-dialysis chronic kidney disease. Toxins. 2019;11(10):589.
   Web of Science ®Google Scholar
• Shu C, Chen X, Xia T, et al. LC-MS/MS method for simultaneous determination of serum p-cresyl sulfate and indoxyl sulfate in patients undergoing peritoneal dialysis. Biomed Chromatogr. 2016;30(11):1782–1788.
   PubMed Web of Science ®Google Scholar
• Hou JS, Wang CH, Lai YH, et al. Serum malondialdehyde-modified low-density lipoprotein is a risk factor for central arterial stiffness in maintenance hemodialysis patients. Nutrients. 2020;12(7):2160.
   Web of Science ®Google Scholar
• Lai YH, Wang CH, Kuo CH, et al. Serum P-cresyl sulfate is a predictor of central arterial stiffness in patients on maintenance hemodialysis. Toxins. 2019;12(1):10.
   Web of Science ®Google Scholar
• Hsieh YJ, Hsu BG, Lai YH, et al. Association of low serum L-carnitine levels with aortic stiffness in patients with non-dialysis chronic kidney disease. Nutrients. 2020;12(10):2918.
   Web of Science ®Google Scholar
• Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445–448.
   PubMed Web of Science ®Google Scholar
• Sedaghat S, Mattace-Raso FU, Hoorn EJ, et al. Arterial stiffness and decline in kidney function. CJASN. 2015;10(12):2190–2197.
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P. Arterial stiffness: a new surrogate end point for cardiovascular disease? J Nephrol. 2007;20 (Suppl 12):S45–S50.
   PubMedGoogle Scholar
• Ramirez AJ, Christen AI, Sanchez RA. Serum uric acid elevation is associated to arterial stiffness in hypertensive patients with metabolic disturbances. CHYR. 2018;14(2):154–160.
   Google Scholar
• Levisianou D, Melidonis A, Adamopoulou E, et al. Impact of the metabolic syndrome and its components combinations on arterial stiffness in Type 2 diabetic men. Int Angiol. 2009;28(6):490–495.
   PubMed Web of Science ®Google Scholar
• Schram MT, Henry RM, van Dijk RA, et al. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension. 2004;43(2):176–181.
   PubMed Web of Science ®Google Scholar
• Semba RD, Najjar SS, Sun K, Lakatta EG, et al. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens. 2009;22(1):74–79.
   PubMed Web of Science ®Google Scholar
• Agnoletti D, Mansour AS, Zhang Y, et al. Clinical interaction between diabetes duration and aortic stiffness in type 2 diabetes mellitus. J Hum Hypertens. 2017;31(3):189–194.
   PubMed Web of Science ®Google Scholar
• Wu IW, Hsu KH, Lee CC, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant. 2011;26(3):938–947.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Liu HL, Pan CF, et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch Med Res. 2012;43(6):451–456.
   PubMed Web of Science ®Google Scholar
• Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. CJASN. 2009;4(10):1551–1558.
   PubMed Web of Science ®Google Scholar
• Tumur Z, Niwa T. Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells. Am J Nephrol. 2009;29(6):551–557.
   PubMed Web of Science ®Google Scholar
• Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int. 2004;65(2):442–451.
   PubMed Web of Science ®Google Scholar
• Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. CJASN. 2011;6(1):30–39.
   PubMed Web of Science ®Google Scholar
• Dou L, Jourde-Chiche N, Faure V, et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost. 2007;5(6):1302–1308.
   PubMed Web of Science ®Google Scholar
• Muteliefu G, Enomoto A, Jiang P, et al. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant. 2009;24(7):2051–2058.
   PubMed Web of Science ®Google Scholar
• Muteliefu G, Shimizu H, Enomoto A, et al. Indoxyl sulfate promotes vascular smooth muscle cell senescence with upregulation of p53, p21, and prelamin A through oxidative stress. Am J Physiol. 2012;303(2):C126–C134.
   Google Scholar
• Niwa T, Nomura T, Sugiyama S, et al. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kid Int Suppl. 1997;62:S23–S28.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Kawagoe Y, Matsuda T, et al. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res. 2004;27(2):121–126.
   PubMed Web of Science ®Google Scholar